These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 6416260)
41. [The reaction of beta-propiolactone with serum proteins and amino acid derivatives (author's transl)]. Determann H; Joachim HU Z Klin Chem Klin Biochem; 1971 Sep; 9(5):398-401. PubMed ID: 5173516 [No Abstract] [Full Text] [Related]
42. Anticomplementary activity and the safety of intravenous immunoglobulin. Rousell RH; Budinger MD; Keppler DC; Victor R; Minaga T Clin Ther; 1989; 11(1):143-50. PubMed ID: 2497981 [TBL] [Abstract][Full Text] [Related]
43. [Use of beta-propiolactone in disinfection and sterilization. (According to foreign investigations)]. BAZHINOV AG; KAMORSKII NM Zh Mikrobiol Epidemiol Immunobiol; 1960 Jul; 31():26-30. PubMed ID: 13688173 [No Abstract] [Full Text] [Related]
44. Effect of beta-propiolactone on bacteriophages and Salmonella typhimurium. Fukuda S; Yamamoto N Cancer Res; 1970 Mar; 30(3):830-3. PubMed ID: 4912945 [No Abstract] [Full Text] [Related]
45. Physical and chemical methods of inactivating Lassa virus. Lloyd G; Bowen ET; Slade JH Lancet; 1982 May; 1(8280):1046-8. PubMed ID: 6122855 [No Abstract] [Full Text] [Related]
46. Principles of selective inactivation of viral genome. V. Rational selection of conditions for inactivation of the viral suspension infectivity to a given extent by the action of beta-propiolactone. Budowsky EI; Zalesskaya MA Vaccine; 1991 May; 9(5):319-25. PubMed ID: 1872015 [TBL] [Abstract][Full Text] [Related]
47. An evaluation of beta-propiolactone for the sterilization of fermentation media. HIMMELFARB P; READ RB; LITSKY W Appl Microbiol; 1961 Nov; 9(6):534-7. PubMed ID: 13907502 [TBL] [Abstract][Full Text] [Related]
48. [Effects of immunoglobulin (Intraglobin) on tendency toward infection in chronic lymphatic leukemia]. Hovgaard D; Hansen MM Ugeskr Laeger; 1987 Nov; 149(46):3097-9. PubMed ID: 3127974 [No Abstract] [Full Text] [Related]
50. An evaluation of the safety of three intravenous immunoglobulin preparations in patients with primary hypogammaglobulinaemia. Yap PL; McClelland DB J Infect; 1986 Jan; 12(1):5-10. PubMed ID: 3082994 [TBL] [Abstract][Full Text] [Related]
51. [Problems in the development of immunoglobulin preparations]. Friedli H Beitr Infusionsther; 1989; 24():95-101. PubMed ID: 2481555 [TBL] [Abstract][Full Text] [Related]
52. Inactivation of virus in intravenous immunoglobulin G using solvent/detergent treatment and pasteurization. Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Sharifi Z Hum Antibodies; 2008; 17(3-4):79-84. PubMed ID: 19029665 [TBL] [Abstract][Full Text] [Related]
53. A retrospective study of immunoglobulin treatment as part of a multi-factorial therapy in children with acute lymphatic leukemia. Kornhuber B Arzneimittelforschung; 1981; 31(11):1930-1. PubMed ID: 6797446 [TBL] [Abstract][Full Text] [Related]
54. Effect of beta-propiolactone on human red cell antigens and antibodies. Kalish RI; Linden JV; Tweedy CJ Transfusion; 1987; 27(2):214-5. PubMed ID: 3824485 [No Abstract] [Full Text] [Related]
55. Effect of combined beta-propiolactone/ultraviolet irradiation treatment on hepatitis B virus. Prince AM; Stephan W Lancet; 1980 Oct; 2(8200):917. PubMed ID: 6107566 [No Abstract] [Full Text] [Related]
56. Method for disinfecting large enclosures with beta-propiolactone vapor. SPINER DR; HOFFMAN RK Appl Microbiol; 1960 May; 8(3):152-5. PubMed ID: 13833363 [No Abstract] [Full Text] [Related]
57. Antioxidants reduce the mutagenic effect of malonaldehyde and beta-propiolactone. Part IX. Antioxidants and cancer. Shamberger RJ; Corlett CL; Beaman KD; Kasten BL Mutat Res; 1979 Apr; 66(4):349-55. PubMed ID: 379630 [TBL] [Abstract][Full Text] [Related]
58. Inactivation of mycoplasmas by use of phenol, formalin and beta-propiolactone. Koski TA; Christianson GG; Cole FL J Biol Stand; 1976 Apr; 4(2):151-4. PubMed ID: 819443 [No Abstract] [Full Text] [Related]